Koers Hutchison China MediTech Limited London S.E.
Aandelen
KYG4672N1198
Farmaceutische producten
Omzet 2024 * | 686 mln. 0 635 mln. | Omzet 2025 * | 842 mln. 0 780 mln. | Marktkapitalisatie | 3,76 mld. 0 3,48 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -107 mln. - -99,11 mln. | Nettowinst (verlies) 2025 * | -2 mln. - -1,85 mln. | EV/omzet 2024 * | 5,19 x |
Nettoliquiditeiten 2024 * | 199 mln. 0 184 mln. | Nettoliquiditeiten 2025 * | 306 mln. 0 283 mln. | EV/omzet 2025 * | 4,1 x |
K/w-verhouding 2024 * |
-32,5
x | K/w-verhouding 2025 * |
684
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 52,37% |
Recentste transcriptie over Hutchison China MediTech Limited
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Wei Guo Su
CEO | Chief Executive Officer | 66 | 01-01-05 |
Chig Fung Cheng
DFI | Director of Finance/CFO | 57 | 01-07-08 |
Michael Shi
CTO | Chief Tech/Sci/R&D Officer | 59 | 01-01-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chi Keung To
CHM | Chairman | 72 | 01-01-00 |
Graeme Jack
BRD | Director/Board Member | 73 | 01-03-17 |
Dan Eldar
BRD | Director/Board Member | 70 | 01-08-16 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+30,38% | 684 mld. | |
+29,75% | 568 mld. | |
-4,36% | 361 mld. | |
+19,30% | 329 mld. | |
+3,73% | 284 mld. | |
+15,87% | 240 mld. | |
+9,30% | 208 mld. | |
-7,36% | 200 mld. | |
+7,68% | 166 mld. |